Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A look at the results from the Phase 3 ICONIC-LEAD study of icotrokinra (JNJ-2113) in patients 12 years of age and older with moderate to severe plaque psoriasis.

Ticker(s): JNJ, PTGX

Who's the expert?

Institution: DOCS Dermatology

Board-certified Dermatologist with 17 years experience
Treats 250 patients with plaque psoriasis
Research interest and clinical trials focusing on atopic dermatitis, acne, alopecia areata, hidradenitis suppurativa and psoriasis.

Interview Goal

On this call we will be discussing the topline results from the Phase 3 ICONIC-LEAD Study of icotrokinra (JNJ-2113), an oral peptide targeting the IL-23 receptor, in patients 12 years of age and older with moderate to severe plaque psoriasis.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.